Eli Lilly & CO Form 4 insider transactions

Lilly Endowment Inc. sold over 179,000 shares of Eli Lilly & Co. common stock in multiple transactions on June 6, 2024.

Lilly Endowment Inc. sold 20,383 shares of Eli Lilly & Co. common stock in multiple transactions on June 5, 2024, at weighted average prices of $836.14 and $837.653.

Eli Lilly's Executive Vice President and Chief Information and Digital Officer, Diogo Rau, reported the acquisition of 6,300 shares of common stock through the vesting of restricted stock units and the disposition of 3,045 shares to cover tax obligations.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co, sold a substantial number of shares in multiple transactions on June 3, 2024.

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 750 shares of common stock at $819.47 per share on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

An Eli Lilly executive, Johna Norton, sold 7,056 shares of common stock at a weighted average price of $819.38, under a pre-arranged 10b5-1 trading plan.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on May 31, 2024.

Lilly Endowment Inc. sold a total of 128,385 shares of Eli Lilly & Co. common stock on May 29, 2024, at various weighted average prices.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold 2,052 shares of common stock at a price of $809 per share on May 28, 2024.

Lilly Endowment Inc. sold 92,563 shares of Eli Lilly & Co. at a weighted average price of $809.211 per share on May 24, 2024.

Lilly Endowment Inc. sold a total of 49,760 shares of Eli Lilly & Co. common stock on May 23, 2024, at various prices.

Lilly Endowment Inc. sold 12,974 shares of Eli Lilly & Co. at a weighted average price of $804.184 per share on May 22, 2024.

Lilly Endowment Inc. sold a total of 180,359 shares of Eli Lilly & Co. common stock in multiple transactions on May 21, 2024, at prices ranging from $804.00 to $813.03.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 19 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 12 shares of common stock through a deferral plan.

Mary Lynne Hedley, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan, while also reporting indirect ownership of 98 shares held in a trust.

Director Ralph Alvarez acquired 15 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 20 shares of Eli Lilly stock through a deferral plan, at a price of $750.77 per share.

Director Kimberly H. Johnson acquired 13 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan, while also holding 98 shares indirectly through a trust.

Director Ralph Alvarez acquired 16 shares of Eli Lilly common stock through a deferral plan, increasing his total holdings to 54,029 shares.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 19 shares of Eli Lilly common stock at $762.66 per share through a deferral plan.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan.

Mary Lynne Hedley, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan, while also holding 98 shares indirectly through a trust.

Eli Lilly director Ralph Alvarez acquired 15 shares of common stock through a deferral plan, as reported in a recent SEC filing.

A recent SEC filing reveals that Eli Lilly's SVP of Finance and CAO, Donald A. Zakrowski, sold 750 shares of common stock and corrected a previous omission of restricted stock unit grants.

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan on February 20, 2024.